ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron